<p>Cells were cultured with vehicle (<i>white bar</i>), 1 μM 9-<i>cis-</i>RA (<i>black bar</i>), 15 μM troglitazone (<i>gray bar</i>), or 15 μM and 1 μM troglitazone and 9-<i>cis</i>-RA (<i>hatched bar</i>), respectively, for 72 hrs. BrdU incorporation was assessed by ELISA and proliferation values were normalized using Percent Vehicle = (Abs<sub>(treatment)</sub>/Abs<sub>(vehicle)</sub>) X 100. Results are shown as means ± SD, n = 6, LSD was used to test for differences among groups. Means followed by the same letter are not significantly different (P = 0.01).</p
<p>After 72h of continuous exposure to drugs (either trastuzumab or fulvestrant as single agents) hi...
<p>Twenty-four h after seeding of cells (0 h time of treatment in the figure), NSpd, Pd-NSpd or Pt-N...
<p>Tα1 or Tα1-iRGD was added to the cell suspension and incubated for 36 h and counted by MTT assay....
<p>(A) K562 cells cultured for 72 hrs in the presence of vehicle (<i>white bars</i>), 1 μM 9-<i>cis<...
<p>(A) The extent of mAb SAM-1 (anti-α5) binding to K562 cells exposed to vehicle, 9-<i>cis</i>-RA, ...
<p>HRTEC were incubated with 10/ml of either Stx2 or SubAB for different times (<b>A</b>). Both toxi...
<p>Ovcar3 cells were serum starved for 24 hours and treated for an additional 24 hours with vehicle ...
<p>K562 cells were cultured for 72 μM 9-<i>cis</i>-RA, 15 μM troglitazone, or 1 μM 9-<i>cis</i>-RA a...
<p>(A) Microtiter wells were coated with 5 μg/mL fibronectin, FN-120, or vitronectin. K562 cells cul...
<p>(A) Basal cell proliferation of human breast cell lines was analyzed using the BrdU incorporation...
<p>MDA-MB-231 tumor cells treated with either vehicle or roziglitazone (Ros), troglitazone (Trog), T...
<p>Ovcar3 cells were double transfected, serum starved for 24 hours and treated for an additional 24...
<p>(A) BrdU immunocytochemistry assay. Left column: control group (CTR), centre: “starved” group (ST...
<p>(A) HT29 cells were pretreated with the β1-AR antagonist ATE (50 µM) or β2-AR antagonist ICI (50 ...
<p>(A–C) Cell proliferation assay. BHP18-21v (A), FRO (B) or WRO (C) cells were incubated in T3-depl...
<p>After 72h of continuous exposure to drugs (either trastuzumab or fulvestrant as single agents) hi...
<p>Twenty-four h after seeding of cells (0 h time of treatment in the figure), NSpd, Pd-NSpd or Pt-N...
<p>Tα1 or Tα1-iRGD was added to the cell suspension and incubated for 36 h and counted by MTT assay....
<p>(A) K562 cells cultured for 72 hrs in the presence of vehicle (<i>white bars</i>), 1 μM 9-<i>cis<...
<p>(A) The extent of mAb SAM-1 (anti-α5) binding to K562 cells exposed to vehicle, 9-<i>cis</i>-RA, ...
<p>HRTEC were incubated with 10/ml of either Stx2 or SubAB for different times (<b>A</b>). Both toxi...
<p>Ovcar3 cells were serum starved for 24 hours and treated for an additional 24 hours with vehicle ...
<p>K562 cells were cultured for 72 μM 9-<i>cis</i>-RA, 15 μM troglitazone, or 1 μM 9-<i>cis</i>-RA a...
<p>(A) Microtiter wells were coated with 5 μg/mL fibronectin, FN-120, or vitronectin. K562 cells cul...
<p>(A) Basal cell proliferation of human breast cell lines was analyzed using the BrdU incorporation...
<p>MDA-MB-231 tumor cells treated with either vehicle or roziglitazone (Ros), troglitazone (Trog), T...
<p>Ovcar3 cells were double transfected, serum starved for 24 hours and treated for an additional 24...
<p>(A) BrdU immunocytochemistry assay. Left column: control group (CTR), centre: “starved” group (ST...
<p>(A) HT29 cells were pretreated with the β1-AR antagonist ATE (50 µM) or β2-AR antagonist ICI (50 ...
<p>(A–C) Cell proliferation assay. BHP18-21v (A), FRO (B) or WRO (C) cells were incubated in T3-depl...
<p>After 72h of continuous exposure to drugs (either trastuzumab or fulvestrant as single agents) hi...
<p>Twenty-four h after seeding of cells (0 h time of treatment in the figure), NSpd, Pd-NSpd or Pt-N...
<p>Tα1 or Tα1-iRGD was added to the cell suspension and incubated for 36 h and counted by MTT assay....